enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. GLP-1s: 'We're investing behind this in a big way,' says ...

   www.aol.com/finance/glp-1s-were-investing-behind...

   With a late-stage clinical pipeline running smoothly and strong growth in 2023 of its key market drivers, Amgen is eyeing annual revenue of $32.4 billion on the low end and up to $33.8 billion for ...

3. 2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious - AOL

   www.aol.com/2-reasons-buy-amgen-stock-134500114.html

   In short, Amgen is a massive biopharma, with dozens of pipeline programs and a huge portfolio of products on the market. In the third quarter alone, its top line was $8.5 billion, and it reported ...

4. Amgen: Does Strong Pipeline Portfolio Outweigh High Debt Level?

   www.aol.com/news/amgen-does-strong-pipeline...

   Amgen Inc. was founded in 1980 and is headquartered in California. I am bullish on AMGN stock. Despite the fact that the biotechnology firm has a high level of debt, profitability is strong, the ...

5. Amgen - Wikipedia

   en.wikipedia.org/wiki/Amgen

   AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]

6. 2025’s Five Highest Yielding Dogs of the Dow Could ... - AOL

   www.aol.com/2025-five-highest-yielding-dogs...

   Transporting crude oil and advanced products by pipeline, marine vessel, motor equipment, and rail car ... Amgen Inc. (NASDAQ: AMGN) discovers, ... Interventional Solutions, including ...

7. Arrowhead Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Arrowhead_Pharmaceuticals

   Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease. [ 7 ] On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and ...

8. Patheon - Wikipedia

   en.wikipedia.org/wiki/Patheon

   Patheon is a service brand within Thermo Fisher Scientific's brand portfolio.Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging.

9. Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime ... - AOL

   www.aol.com/news/amgen-amgn-add-stomach-cancer...

   Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.